BRIEF published on 04/24/2026 at 07:05, 2 months 3 days ago BB Biotech AG Reports Q1 2026 Interim Results Drug Development Net Loss Investment Portfolio BB Biotech Q1 2026
BRIEF published on 04/24/2026 at 07:05, 2 months 3 days ago BB Biotech AG publie ses résultats intermédiaires du premier trimestre 2026 Perte Nette Portefeuille D'investissement Développement De Médicaments BB Biotech 1er Trimestre 2026
BRIEF published on 04/24/2026 at 07:05, 2 months 3 days ago Réalisations et évolutions stratégiques de BB Biotech au premier trimestre 2026 Valeur Nette D'actif Nouveaux Investissements Performance De BB Biotech Repositionnement De Portefeuille Inclusion De Dividendes
BRIEF published on 04/24/2026 at 07:05, 2 months 3 days ago BB Biotech Q1 2026 Achievements and Strategic Shifts Net Asset Value Portfolio Repositioning New Investments BB Biotech Performance Dividend Inclusion
PRESS RELEASE published on 04/24/2026 at 07:00, 2 months 3 days ago EQS-Adhoc: BB Biotech AG publishes its interim report BB Biotech AG publishes its interim report for the first quarter of 2026, showing a net loss of CHF 21 mn compared to CHF 241 mn in the same period of 2025 Investment Company BB Biotech AG Interim Report Results Loss
PRESS RELEASE published on 04/24/2026 at 07:00, 2 months 3 days ago BB Biotech Q1 2026: Share price outperformance, narrowing discount and active portfolio repositioning BB Biotech AG reports Q1 2026 results with share price outperformance, narrowing discount, and active portfolio repositioning. Eleven new investments made in biotech sector Share Price BB Biotech AG Investments Portfolio Repositioning Q1 2026
BRIEF published on 03/19/2026 at 17:45, 3 months 7 days ago BB Biotech AG's AGM Approves Proposals and Dividend Annual General Meeting Investment Strategy Board Re-election Dividend Approval BB Biotech
BRIEF published on 03/19/2026 at 17:45, 3 months 7 days ago L'assemblée générale annuelle de BB Biotech AG approuve les propositions et le dividende Stratégie D'investissement Assemblée Générale Annuelle Réélection Du Conseil D'administration Approbation Des Dividendes BB Biotech
PRESS RELEASE published on 03/19/2026 at 17:40, 3 months 7 days ago Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.25 per share Shareholders at BB Biotech AG's AGM approve CHF 2.25 dividend per share. Board proposals endorsed. Re-election of board members Shareholders Dividend AGM BB Biotech AG Board Proposals
BRIEF published on 02/20/2026 at 07:05, 4 months 7 days ago BB Biotech AG publie son rapport annuel 2025 Proposition De Dividende Augmentation Du Bénéfice Net BB Biotech Secteur De La Biotechnologie Rapport Annuel 2025
Published on 06/27/2026 at 01:40, 5 hours 46 minutes ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 7 hours 26 minutes ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 8 hours 26 minutes ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 8 hours 36 minutes ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 9 hours 11 minutes ago Revive Therapeutics Announces Proposed Private Placement
Published on 06/27/2026 at 00:05, 7 hours 21 minutes ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 7 hours 22 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 7 hours 50 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 7 hours 50 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 7 hours 59 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
Published on 06/26/2026 at 17:45, 13 hours 41 minutes ago Descriptif du programme de rachat d'actions
